An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis

Summary

association studies of coronary artery disease (CAD), could include functionally relevant associations. We propose an integrated genomic and transcriptomic approach for unravelling new potential genetic signatures of atherosclerosis. Fifteen among 91 single nucleotide polymorphisms (SNPs) were first selected for association in a sex- and age-adjusted model by examining 510 patients with CAD and myocardial infarction and 388 subjects with normal coronary arteries (CAD-free) in the replication stages of a genome-wide association study. We investigated the expression of 71 genes proximal to the 15 tag-SNPs by two subsequent steps of microarray-based Mrna profiling, the former in vascular smooth muscle cell populations, isolated from non-atherosclerotic and atherosclerotic human carotid portions, and the latter in whole carotid specimens. BCL3 and PVRL2, contiguously located on chromosome 19, and ABCA1, extensively investigated before, were found to be differentially expressed. BCL3 and PVRL2 SNPs were genotyped within a second population of CAD patients (n=442) and compared with CAD-free subjects (n=393). The carriership of the BCL3 rs2965169 G allele was more represented among CAD patients and remained independently associated with CAD after adjustment for all the traditional cardiovascular risk factors (odds ratio=1.70 with 95% confidence interval 1.07–2.71), while the BCL3 rs8100239 A allele correlated with metabolic abnormalities. The upregulation of BCL3 mRNA levels in atherosclerotic tissue samples was consistent with BCL3 protein expression, which was detected by immunostaining in the intima-media of atherosclerotic specimens, but not within non-atherosclerotic ones. Our integrated approach suggests a role for BCL3 in cardiovascular diseases.

Keywords

BCL3 - genomics - transcriptomics - coronary artery disease - metabolic disorders

• References

• 1 Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell 2012; 148: 1242-1257.
• 2 Roger VL. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: 188-197.
• 3 Ding K, Kullo IJ. Genome-wide association studies for atherosclerotic vascular disease and its risk factors. Circ Cardiovasc Genet 2009; 2: 63-72.
• 4 O’Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med 2011; 365: 2098-2109.
• 5 Bijnens APJJ. et al. Genome-wide expression studies of atherosclerosis-Critical issue in methodology, analysis, interpretation of transcriptomics data. Arte-rioscler Thromb Vasc Biol 2006; 26: 1226-1235.
• 6 Miller DT. et al. Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 2007; 49: 1589-1599.
• 7 Cappola TP, Margulies KB. Functional genomics applied to cardiovascular medicine. Circulation 2011; 124: 87-94.
• 8 Park SW. et al. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004; 279: 50630-50638.
• 9 Lambert G. et al. Molecular basis of PCSK9 function. Atherosclerosis 2009; 203: 1-7.
• 10 Musunuru K. et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010; 466: 714-719.
• 11 Yang X. Use of functional genomics to identify candidate genes underlying human genetic association studies of vascular diseases. Arterioscler Thromb Vasc Biol 2012; 32: 216-222.
• 12 Marian AJ, Belmont J. Strategic approaches to unravelling genetic causes of cardiovascular diseases. Circ Res 2011; 108: 1252-1269.
• 13 Stahl EA. et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012; 44: 483-489.
• 14 Park JH. et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010; 42: 570-575.
• 15 Ross R. Mechanisms of disease: Atherosclerosis-An inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 16 Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
• 17 Campbell JH, Campbell GR. Smooth Muscle Phenotypic Modulation—A Personal Experience. Arterioscler Thromb Vasc Biol 2012; 32: 1784-1789.
• 18 Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012; 95: 156-164.
• 19 Hao H. et al. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 2003; 23: 1510-1520.
• 20 Doran AC. et al. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 812-819.
• 21 Lacolley P. et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 2012; 95: 194-204.
• 22 Johnson JL. Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis. Cardiovasc Res. 2014 Epub ahead of print.
• 23 Motterle A. et al. Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet 2012; 21: 4021-4029.
• 24 Perisic L. et al. Profiling of atherosclerotic lesions by gene and tissue microar-rays reveals PCSK6 as a novel protease in unstable carotid atherosclerosis. Arte-rioscler Thromb Vasc Biol 2013; 33: 2432-2443.
• 25 Bozzini C. et al. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thromb Haemost 2004; 92: 541-549.
• 26 Martinelli N. et al. Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile. Blood 2010; 116: 5688-5697.
• 27 Kathiresan S. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
• 28 Matthews DR. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
• 29 North American Symptomatic Carotid EndarterectomyTrial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with highgrade carotid stenosis. N Engl J Med 1991; 325: 445-453.
• 30 Coen M. et al. Calmodulin expression distinguishes the smooth muscle cell population of human carotid plaque. Am J Pathol 2013; 183: 996-1009.
• 31 Skalli O. et al. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986; 103: 2787-2796.
• 32 Cui X, Churchill GA. Statistical tests for differential expression in cDNA micro-array experiments. Genome Biol 2003; 4: 210-219.
• 33 Altman DG. Statistics and ethics in medical research. How large a sample? Br Med J 1980; 281: 1336-1338.
• 34 Lake SL. et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55: 56-65.
• 35 Park BY. et al. Differential parental transmission of markers in BCL3 among Korean cleft case-parent trios. J Prev Med Public Health 2009; 42: 1-4.
• 36 Reilly MP. et al. Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011; 377: 383-392.
• 37 Folkersen L. et al. BiKE and ASAP study groups. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 365-373.
• 38 Ramsey SA. et al. A systems biology approach to understanding atherosclerosis. EMBO Mol Med 2010; 2: 79-89.
• 39 Maouche S, Schunkert H. Strategies beyond genome-wide association studies for atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 170-181.
• 40 Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006; 99: 1031-1043.
• 41 Fitzgerald ML. et al. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; 211: 361-370.
• 42 Talmud PJ. et al. Gene-centric association signals for lipids and apolipoproteins identified via the Human CVD BeadChip. Am J Hum Genet 2009; 85: 628-642.
• 43 Fransen K. et al. Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn’s disease. Hum Mol Genet 2010; 19: 3482-3488.
• 44 Miller AM, McInnes IB. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr Pharm Des 2011; 17: 1-8.
• 45 Palmer S, Chen YH. Bcl-3, a multifaced modulator of NF-kB-mediated gene transcription. Immunol Res 2008; 42: 210-218.
• 46 Hinz M. et al. It takes two to tango: IkBs, the multifunctional partners of NF-kB. Immunol Rev 2012; 246: 59-76.
• 47 Yang J. et al. BCL3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha. Mol Cell Biol 2009; 29: 4091-4102.
• 48 Alberti KG. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
• 49 Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399-404.
• 50 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.